SAN DIEGO, June 5, 2020 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of molecular
technologies designed to provide physicians with clinically
actionable information to improve the outcomes of patients with
cancer, announces that it is relocating its corporate offices and
CLIA-certified, CAP-accredited high complexity laboratory to a new
location in San Diego. The move is expected to be completed by
2020 year end.
The company's new 39,000-square-foot headquarters, manufacturing
and lab facility will be located at 9955 Mesa Rim Road,
San Diego, CA 92121.
"This location is well-suited to meet our commercial,
development and administrative needs and aligns with our strategy
of supporting growth while reducing rent expense and other facility
costs," said Tim Kennedy, CFO and
Senior Vice President of Operations of Biocept. "Our CLIA
license will be transferred to the new location with our move and
we anticipate a smooth transition without workflow
disruption."
"We are grateful to call San
Diego our home and to find a well-suited location that is
convenient for our employees," said Michael
Nall, President and CEO of Biocept. "We look forward to
this next chapter in Biocept's history and further fulfilling our
commitment to commercializing innovative diagnostic solutions that
provide needed information for improving the outcomes of patients
diagnosed with cancer."
About Biocept
Biocept, Inc. is a molecular diagnostics
company with commercialized assays for lung, breast, gastric,
colorectal and prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
clinically actionable information for treating and monitoring
patients diagnosed with cancer. The Company's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. For additional
information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. To the extent that statements in this
release are not strictly historical, including without limitation
statements as to our ability to improve the outcomes of patients
diagnosed with cancer, the timing of the move to our new facility,
our ability smoothly transition without workflow disruption to our
new facility, and our ability to provide physicians with clinically
actionable information for treating and monitoring patients
diagnosed with cancer, such statements are forward-looking, and are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The reader is cautioned
not to put undue reliance on these forward-looking statements, as
these statements are subject to numerous risk factors as set forth
in our Securities and Exchange Commission (SEC) filings. The
effects of such risks and uncertainties could cause actual results
to differ materially from the forward-looking statements contained
in this release. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law. Readers are advised to review our filings with the SEC, which
can be accessed over the Internet at the SEC's website located at
www.sec.gov.
Investor Contact:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-to-relocate-corporate-offices-and-clia-certified-laboratory-to-new-san-diego-location-301070634.html
SOURCE Biocept, Inc.